FDA Approvals Roundup: Kloxxado, Farxiga, Ferriprox
The Pharma Data
MAY 5, 2021
It also provided supporting pharmacokinetic data demonstrating the opioid antagonist’s safety and efficacy. . Farxiga use expanded for reducing risks in patients with chronic kidney disease. Among study arm patients, 100 were hospitalized for heart failure or had a CV-related death, compared with 138 patients in the placebo arm. .
Let's personalize your content